Howard Adelglass is a New York, New York based physiatrist who is specialized in Pain Management (PM&R). Active license number of Howard Adelglass as Pain Management (PM&R) is 148023NY in New York.
Howard Adelglass provides a high level of care, either as a primary physician or consultant, for patients experiencing problems with acute, chronic or cancer pain in both hospital and ambulatory settings. Patient care needs may also be coordinated with other specialists.
Complete Profile:
Howard Adelglass speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Pain Management (PM&R)
Credentials:
MD
Gender:
Male
Practice Address:
200 Central Park South, Suite 212, New York, New York, 10019
Phone:
646-707-0533
Fax:
917-456-0348
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1962427427
NPI Enumeration Date:
13 Jul, 2006
NPI Last Update On:
21 Jul, 2022
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Howard Adelglass are as mentioned below.
License Number
Specialization
State
Status
148023NY
Pain Management
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
151 E 80th St, Apt 2c New York, New York
Zip:
10021-0442
Phone Number:
646-707-0533
Fax Number:
917-456-0348
Patients can reach Howard Adelglass at 200 Central Park South, Suite 212, New York, New York or can call to book an appointment on 646-707-0533. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 July, 2025.